With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma
This article was originally published in PharmAsia News
Executive Summary
Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.